Challenges in assessing asthma severity in clinical practice

Advanced Studies in Medicine

Volumn 3, Issue 5 A, 2003, Pages

  Spahn, Joseph ^a   Calhoun, William J ^b,c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID;

ASTHMA; CAUSE OF DEATH; CLINICAL PRACTICE; DECISION MAKING; DETERIORATION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; HEALTH CARE ORGANIZATION; HEALTH STATUS; HUMAN; INFECTION CONTROL; LUNG FUNCTION; PATIENT CARE; PATIENT MONITORING; PRESCRIPTION; PREVENTIVE MEDICINE; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING; WELLBEING;

EID: 0038176112     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: US Department of Health and Human Services, National Institutes of Health; 1997. NIH publication 97-4051.
2. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. Bethesda, Md: US Department of Health and Human Services, National Institutes of Health; 2002. NIH publication 02-5075.
3. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the National Asthma Education and Prevention Program Guidelines. Am J Respir Crit Care Med. 2002;166:1044-1049.
4. Osborne ML, Vollmer WM, Pedula KL, Wilkins J, Buist AS, O'Hollaren M. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest. 1999; 115:85-91.
5. Wenzel SE. Factors determining the severity of asthma. Clin Exp Allergy. 1998;28(suppl 5):119-125.
6. Bailey WC, Higgins DM, Richards BM, et al. Asthma severity: a factor analytic investigation. Am J Med. 1992;93:263-269.
7. Wijnhoven HA, Kriegsman DM, Hesselink AE, Penninx BW, de Haan M. Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest. 2001;119:1034-1042.
8. Ehrs PO, Aberg H, Larsson K. Quality of life in primary care asthma. Respir Med. 2001;95:22-30.
9. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med. 1995;151:66-70.
10. Moy ML, Israel E, Weiss ST, Juniper EF, Dube L, Drazen JM. Clinical predictors of health-reloted quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001;163:924-929.
11. Annett RD, Bender BG, Lapidus J, Duhamel TR, Lincoln A. Predicting children's quality of life in an asthma clinical trial: what do children's reports tell us? J Pediatr. 2001;139:854-861.
12. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol. 1992;45:461-472.
13. Juniper EF, Guyatt GH, Ferrie PJ, Grifith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832-838.
14. Rutten-van Mölken MP, Custers F, van Doorslaer EK, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J. 1995;8:888-898.
15. Stempel DA. The myth of mild asthma. Ann Allergy Asthma Immunol. 2002;89:340-343.
16. Asthma in America Survey. Available at: http://www.asthmainamerica.com/statistics.htm. Accessed February 15, 2003.
17. Spahn J, Covar R, Stempel DA. Asthma: addressing consistency in results from basic science, clinical trials, and observational experience. J Allergy Clin Immunol. 2002;109: S490-S502.
18. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta-2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992;90:32-42.
19. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med. 1999;159:22-30.
20. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381.
21. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331:700-705.
22. 1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107:61-67.
23. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95-100.
24. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
25. O'Byrne P, Cuddy L, Taylor W, et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in a primary care practice. Can Respir J. 1996;3:169-175.